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Abstract 
Malaria is one of the major health problems of the world. A number of vaccine candidates have been identified and are at 
different stages of the clinical trials. Wide spread deployment of malaria vaccines requires a cost effective and scalable 
production platform. We have chosen a non-pathogenic bacterial host, Bacillus subtilis, to produce a malaria vaccine 
candidate PfMSP5. Merozoite surface protein 5 (MSP5) is present during the asexual stage of Plasmodium falciparum, 
and is a recognized target that can be used as a subunit vaccine against blood stages of malaria. PfMSP5 was successfully 
expressed in B. subtilis and recovered from the culture supernatant in single step (nickel-affinity chromatography) 
purification. B. subtilis derived PfMSP5 induced very strong immune responses in mouse immunization experiments. The 
antibodies raised against PfMSP5 were reactive with proteins expressed by the parasite as shown by immunofluorescence. 
Our results conclude that the B. subtilis is an efficient expression host for the production of the malaria vaccine candidate 
PfMSP5. 
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1. Introduction 
Malaria is an infectious disease caused by the parasite genus Plasmodium. More than 2.3 billion people are 
living at the risk of malaria [1]. The Plasmodium falciparum parasite causes a severe form of malaria and is 
responsible for majority of the deaths, mainly happening in children under the age of 5 years [2]. Although 
drugs are available for the treatment of malaria, they are expensive; furthermore resistance to these drugs is 
widespread [3]. Various control measures have reduced the burden of malaria in the past decade. However, 
sustained control requires the development of additional tools including a protective vaccine. A number of 
proteins taken from various stages of the parasite’s life cycle have been demonstrated to be potential vaccine 
candidates, and are in various stages of clinical trials [3,4]. For the asexual blood stage, one of the highly 
regarded candidate antigens is merozoite surface protein 5 (MSP5) [5]. MSP5 has an epidermal growth factor-
like (EGF-like) domain on its C-terminus, which is conserved among the several malarial species examined 
[6]. It has been characterized [6,7] and is found immunogenic in the natural process of infection [8]. MSP5 is 
expressed by different forms of the parasite and at different stages of the life cycle, i.e. merozoites, 
sporozoites and infected hepatocytes [9] and therefore antibodies raised against MSP5 would be effective for 
both liver and blood-stages of malaria [5]. MSP4/5 is a homologue of both MSP5 and another protein, MSP4, 
in the rodent malaria species P. yoelii [10]. MSP4/5 has been found effective in inducing protection against a 
lethal challenge from studies with mice immunized with recombinant PyMSP4/5 [11]. Therefore, MSP5 is an 
attractive antigen to include in the malaria vaccine cocktail.  
Efficient MSP5 synthesis using a range of different expression systems was found to be difficult [12]. This 
is likely because MSP5 is a membrane protein with extensive intramolecular linkages. The conserved EGF-
like domain contains 3 intramolecular disulphide linkages which are essential to form antigenic epitopes [13]. 
In the present study, we have attempted to use an alternative expression platform, the Gram positive 
bacterium Bacillus subtilis.  B. subtilis is a non-pathogenic [14], fast growing [15] organism, which does not 
produce any endotoxins. It has been used for the production of food and industrial enzymes at large scales 
[16]. In addition to this, it has the ability to secrete target proteins into the culture medium in a functional 
form; this assists with the separation of the product protein in its native form, thus reducing purification costs 
significantly. An internal quality control mechanism in B. subtilis [17] eliminates the possibility of secreting 
misfolded or incompletely synthesized proteins and allows only full length proteins in functional form to be 
secreted; this is essential especially for medical applications.  
The present study evaluates the ability of B. subtilis to produce the malaria vaccine candidate PfMSP5 and 
to evaluate its ability to induce protective antibodies against Plasmodium parasite infection. 
2. Materials and methods 
2.1. Cloning of PfMSP5 
An E. coli codon-optimized gene encoding mature PfMSP5 (lacking N-terminal signal sequence and also 
C-terminal GPI anchored region) was amplified from the vector pET24d-PfMSP5.  A set of PCR primers was 
designed to amplify the coding region, which incorporated an XbaI site at 5’ end and an XmaI site at the 3’end. 
The reverse primer also contained a sequence encoding for a hexahistidine tag. The product was digested with 
XbaI & XmaI, and then ligated into an E. coli / B. subtilis shuttle vector pHT43 (carries a signal sequence to 
direct target proteins into culture media) (MoBiTec, Göttingen, Germany), linearized with the same restriction 
enzymes, resulting in plasmid pHT43-PfMSP5. After sequencing analysis confirming that the nucleotide 
sequence of PfMSP5 in pHT43-PfMSP5 was correct, the plasmid was transferred to B. subtilis WB800N 
(MoBiTec, Göttingen, Germany).  
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2.2. Expression of PfMSP5 by B. subtilis 
Recombinant B. subtilis cells were grown on rich media described elsewhere [18], supplemented with  1 g 
L-1 of MgSO4 and 3 mL L-1 of Trace element solution [19]. Recombinant protein expression was induced by 
adding 1mM IPTG (Progen Industries Limited, Darra, Queensland, Australia). Culture supernatant, collected 
by centrifugation (15344g for 10 minutes at 4oC), was analyzed for the presence of recombinant proteins by 
fractionation on 12% SDS-PAGE and Coomassie staining. A second gel loaded with an aliquot of the 
identical samples was run in parallel, and then blotted onto a polyvinylidene fluoride (PVDF) membrane 
(BioTrace™ PVDF Transfer Membrane, PALL, Gelman Laboratory, USA) and probed with anti-PfMSP5 
mouse monoclonal antibodies (Hybridoma supernatant at 1:1000 dilution) raised against PfMSP5 expressed in 
E. coli. Goat anti-mouse antibodies conjugated with HRP (EMD Millipore, Billerica, MA, USA) (dilution 
1:2000) were used as secondary antibodies and developed using Lumi-Light chemiluminescent substrate 
(Roche Applied Science, Indianapolis, IN, USA). 
2.3. PfMSP5 purification and characterization 
PfMSP5 produced in B. subtilis (hereafter referred to as BsPfMSP5) was recovered from culture 
supernatant using immobilized metal affinity chromatography (IMAC) [20]. A chromatographic column (XK-
16) (GE Healthcare, Pittsburgh, PA, USA) was packed with chelating sepharose fastflow (GE Healthcare, 
Pittsburgh, PA, USA) resin and was charged with 0.1 M NiSO4. The culture supernatant was passed through 
the column using an FPLC (AKTA Prime) (GE Healthcare, Pittsburgh, PA, USA) system and bound protein 
was eluted using 0.4 M imidazole buffer. The resultant protein was analysed by 12 % SDS-PAGE and the 
concentration was determined by Bio-Rad protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA). The 
MSP5 content in the purified protein was estimated by densitometry of Commassie stained SDS-PAGE using 
Image J (http://rsb.info.nih.gov/ij/). The purified PfMSP5 was subjected to MALDI-MS on a 4700 Proteomics 
Discovery System instrument (Applied Biosystems, Calsbad, CA).  
2.4. Immunogenicity of BsPfMSP5 
Groups of female BALB/c mice (n=8, power 85%, p<0.05), aged 6-8 weeks were used for the 
immunization experiment. Purified recombinant BsPfMSP5 (25 μg per mice per dose) was emulsified with 
Freund’s adjuvant (complete Freund’s adjuvant for primary injection and incomplete Freund’s adjuvant for 
the remaining injections) and injected intraperitoneally (ip) at weeks 0, 3 and 6. Antisera samples were 
collected two weeks after each injection. 
2.5. Antibody analysis 
Antibody response in the immunized mice against the BsPfMSP5 antigen was measured by indirect 
enzyme linked immunosorbent assay (ELISA) described elsewhere [21]. BsPfMSP5 or PBS (negative control) 
was used as solid phase coating antigen. The optical density (OD) was read at 405 nm, and the OD value for 
the PBS control was subtracted from the OD values obtained with BsPfMSP5 coated wells to obtain a specific 
OD for the response to BsPfMSP5. Antisera were tested in duplicates at 2-fold serial dilutions and the titer 
was defined as the reciprocal of the highest dilution which gave a specific OD value greater than 0.1 [22]. For 
the determination of IgG profiles, a series of alkaline phosphatase-conjugated anti-mouse immunoglobulin 
subclasses, IgG1, IgG2a, IgG2b, IgG3 and IgM (Southern Biotechnology Associate Inc., Birmingham, AL) 
were used as secondary antibodies [23].   
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2.6. Indirect Immunofluorescent assay (IFA) 
Reactivity of mouse antibodies raised against BsPfMSP5 to parasite proteins was determined by 
immunofluorescent assay. The IFA was performed as previously described [24]. Anti-MSP5 mouse antibodies 
and Alexa Fluor 488-conjugated anti-mouse immunoglobulin (Molecular Probes, Inc., Eugene, OR) were 
used as primary and secondary antibodies respectively. 
2.7. Statistical analysis 
The difference between two groups of animal data was evaluated by a t-test with unequal variance using 
GraphPad Prism 5 software (GraphPad Software Inc., La Jolla, CA, USA).  
3. Results and Discussion 
3.1. Expression of PfMSP5 in B. subtilis 
PfMSP5 was expressed in B. subtilis using the pHT43 vector. Secreted BsPfMSP5 was recovered from the 
culture supernatant by nickel affinity chromatography. The yield of BsPfMSP5 was estimated by 
densitometry, to be 5 mg per liter. 
 
Fig. 1. (a) Expression of PfMSP5 by B. subtilis; (b) Western blot analysis of PfMSP5 produced by B. subtilis. Lane M. Molecular weight 
marker, Lane 1. EcPfMSP5 (non-reduced), Lane 2. BsPfMSP5 (non-reduced), lane 3. EcPfMSP5 (reduced), lane 4. BsPfMSP5 (reduced), 
lane 5. Negative control. For detection, anti-PfMSP5 monoclonal antibodies (cocktail) are used as primary antibodies. c) Results of mass 
spectrometry for BsPfMSP5 
Quality of the purified BsPfMSP5 was compared to E. coli expressed PfMSP5 (EcPfMSP5) encoded by 
the same gene sequence using SDS-PAGE. As shown in Fig.1 (a), a major band at ~40 kDa was identified, 
which is the expected size of the secreted PfMSP5 product. An identical gel was run and transferred to a 
PVDF membrane and probed with a cocktail of anti-PfMSP5 monoclonal antibodies. As shown in Fig.1 (b), 
PfMSP5 specific antibodies reacted with the B. subtilis expressed PfMSP5 product indicating the presence of 
at least one epitope and confirming that the 40 kDa band is indeed MSP5. These results indicate that the B. 
subtilis can secrete antigenic PfMSP5. 
The theoretically computed size of the protein (http://web.expasy.org/compute_pi/) determined from the 
c
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gene sequence was estimated to be 27951.11 Da. The precise molecular weight determined by mass 
spectrometry gave sizes of 28007.44 Da (Fig.1 (c)), indicating the expression of full length protein by 
Bacillus.  
3.2. Oligomerisation profile of PfMSP5 produced in B. subtilis  
The oligomerisation profile of the proteins was studied under reducing (1mM DTT) and non-reducing 
conditions on SDS-PAGE. As shown in Fig.1 (a), oligomeric forms observed under non-reducing conditions 
disappeared when the sample was run under reducing conditions.  This is consistent with the expected 
sensitivity to reduction of PfMSP5. EcPfMSP5 showed a higher degree of oligomerization than BsPfMSP5 
and some multimeric forms persisted after reduction, suggesting that BsPfMSP5 is homologous to PfMSP5 
which is fully transformed to a monomeric form under reducing conditions. 
3.3. Immunogenicity of BsPfMSP5 
Immunogenicity of BsPfMSP5 was investigated by immunization experiments in mice. A group of 8 mice 
were immunized ip with purified BsPfMSP5 (25 μg per dose) emulsified with Freund’s adjuvant. Mice 
immunized with BsPfMSP5 developed PfMSP5 specific antibodies with a mean titer of 2.7 x 105 (Fig. 2a) 
compared to a mean titer of 50 in unimmunized control mice (p<0.0001). As shown in the Fig. 2(b), the 
majority of the antibodies raised were of the IgG1 subclass along with a moderate amount of IgG2b. A similar 
pattern was observed for antibodies raised against EcPfMSP5 (unpublished data). 
 
Fig. 2. ELISA specific for PfMSP5. (a) Antibody titers measured in mice immunized with PBS (1) and purified BsPfMSP5 emulsified 
with Freund’s adjuvant (2). Mean antibody titers indicated, dots represent individual mice. (b) Antibody isotype profile.  Sera from mice 
were diluted 1 in 5,000.  The error bars represent one standard deviation. 
3.4. Immunofluorescent assay 
An immunofluorescence assay was performed using thin blood smears of schizont stage Plasmodium 
falciparum 3D7 parasites. Anti-PfMSP5 mouse antibodies raised against BsPfMSP5 reacted with schizonts at 
a dilution of 1:100 (Fig. 3).  
The antibodies specifically bound to the infected cells but not to the uninfected red blood cells, as evident 
from phase contrast microscopy, with a pattern typical of MSP5, confirming the specificity of the antibodies. 
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These results indicate that the BsPfMSP5 proteins retained a similar conformation and immunogenic epitopes 
shared by P. falciparum expressed PfMSP5 proteins. In addition, the results indicate that the B. subtilis 
derived proteins are capable of raising antibodies with potentially medical relevance. 
 
Fig. 3. Immunofluorescent assay with mouse antibodies raised against BsPfMSP5. P. falciparum 3D7 schizonts were fixed on a slide 
using acetone: methanol and tested with mouse sera raised against BsPfMSP5. (1) Phase contrast (2) DAPI stained (3) Binding of anti-
mouse antibodies conjugated with Alexfluor 488 dye  and (4) Overlay of (2) and (3) 
4. Conclusions 
This study established the ability of B. subtilis to express and secrete malarial vaccine candidate PfMSP5. 
Mass spectrometry analysis suggests the expression of full length protein by B. subtilis. The expressed protein 
was shown to retain its antigenic epitopes as evident from the Western blot analysis. BsPfMSP5 was 
immunogenic in mice and induced high levels of specific antibodies. These antibodies were functional in 
binding to proteins expressed by P. falciparum. The antibodies bind to parasite MSP5 surface proteins, which 
is essential to block the erythrocyte invasion and thus, malaria. All the above features are essential to 
formulate an effective malaria vaccine or any other high quality clinical material. In conclusion, B. subtilis 
seems to be an ideal vector for the expression of functional and cost effective malarial vaccine candidates. 
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